Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC News
- Adult Immunization
- Hepatology
- Rare Disorders
- Pediatric Immunization
- Weight Management
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Kidney Disease
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Orthopedics
- Obesity Medicine
- Rheumatology
- Technology
- Oncology
- Nephrology
- Neurology
- Pulmonology
Social Determinants of Health and Prevention of Cardiovascular Disease
Research demonstrates that socioeconomic inequalities are "strong determinants" of cardiovascular risk throughout the world.
Members of the writing committee for the American College of Cardiology/American Heart Association 2019 Guideline on Primary Prevention of Cardiovascular Disease incorporated throughout the guideline consideration of how social determinants of health may impact the efficacy of specific guidance and prescriptions for an individual patient. ACC/AHA recommends that clinicians revisit these considerations at each follow-up visit.
Considerations include but are not limited to socioeconomic and educational status as well as cultural, home, and employment environments. The slides below highlight examples of considerations cited by the ACC/AHA for 7 health domains.
Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial
The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor
Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces
"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.
GLP-1/GIP Dual Agonist HRS9531 Shows Promising Phase 2 Data for Obesity Management
More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.
Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial
The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor
Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces
"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.
GLP-1/GIP Dual Agonist HRS9531 Shows Promising Phase 2 Data for Obesity Management
More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.